New evidence on the use of fosfomycin for bacteremia and infectious endocarditis.

Article Details

Citation
Copy to clipboard

Veganzones J, Montero A, Maseda E

New evidence on the use of fosfomycin for bacteremia and infectious endocarditis.

Rev Esp Quimioter. 2019 May;32 Suppl 1:25-29.

PubMed ID
31131589 [ View in PubMed
]
Abstract

There is growing concern regarding the increased resistance rates of numerous pathogens and the limited availability of new antibiotics against these pathogens. In this context, fosfomycin is of considerable interest due to its activity against a wide spectrum of these microorganisms. We will review the encouraging data on this issue regarding the use of fosfomycin in treating Gram-negative bacterial infections. We will also cover fosfomycin's role against 2 of the main causal agents of bacteremia and endocarditis worldwide (nosocomial and community-acquired): enterococci, whose growing resistance to glycopeptides and aminoglycosides represents a serious threat, and methicillin-resistant Staphylococcus aureus, whose infection, despite efforts, continues to be associated with high morbidity and mortality and a high risk of complications. Thanks also to its considerable synergistic capacity with various antibiotics, fosfomycin is a tool for extending the therapeutic arsenal against these types of infections.

DrugBank Data that Cites this Article

Drugs